524606 — Beryl Drugs Cashflow Statement
0.000.00%
- IN₹115.79m
- IN₹158.41m
- IN₹267.30m
- 49
- 41
- 10
- 22
Annual cashflow statement for Beryl Drugs, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 1.58 | 3.48 | -9.5 | 9.84 | 10.1 |
Depreciation | |||||
Non-Cash Items | 1.75 | -1.3 | 2.92 | 2.88 | 3.25 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -8.08 | -11.1 | -7.15 | 3.94 | -17.2 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 1.85 | 3.78 | -2.87 | 24.8 | 8.2 |
Capital Expenditures | -18.8 | -10.5 | -4.16 | -15.6 | -13.5 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 3.21 | 13.1 | 9.53 | 2.62 | 2.7 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -15.5 | 2.55 | 5.38 | -13 | -10.8 |
Financing Cash Flow Items | -3.21 | -4.66 | -4.34 | -4.16 | -4.49 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 16.7 | -5.77 | -4.32 | -11.7 | 1.03 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 2.97 | 0.558 | -1.81 | 0.117 | -1.58 |